![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/07\/20260724_Genmab_AbbVie_Therapeutic_Indications-768x512.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Genmab \/ AbbVie<\/p>\n Event Type<\/strong><\/p>\n Clinical Trial Results Clarification (Phase 3 Confirmatory Endpoint)<\/p>\n Modality<\/strong><\/p>\n Bispecific T-Cell Engager (CD20\u00d7CD3 DuoBody)<\/p>\n Asset<\/strong><\/p>\n Epkinly (epcoritamab-bysp)<\/p>\n Target<\/strong><\/p>\n CD20 \/ CD3<\/p>\n Disease Area<\/strong><\/p>\n Relapsed or Refractory Diffuse Large B-Cell Lymphoma<\/p>\n Genmab and AbbVie clarified on July 23 that overall survival \u2014 the sole U.S. primary endpoint in Phase 3 EPCORE DLBCL-1 \u2014 was not met. The randomized trial had previously shown a progression-free-survival hazard ratio of 0.74 for epcoritamab monotherapy versus investigator-choice chemoimmunotherapy, while overall survival was not statistically significant at a hazard ratio of 0.96. Because the U.S. third-line diffuse large B-cell lymphoma indication remains under accelerated approval, the clarification materially weakens the straightforward confirmatory pathway. It does not establish that FDA will withdraw the indication; the regulatory outcome will depend on the full dataset, trial conduct, endpoint hierarchy, benefit-risk profile, and any additional evidence.<\/p>\n EPCORE DLBCL-1 randomized 483 adults with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for autologous stem-cell transplantation to subcutaneous epcoritamab or investigator choice of rituximab-gemcitabine-oxaliplatin or bendamustine-rituximab. Seventy-three percent had received at least two prior lines.<\/p>\n The January topline disclosure reported progression-free survival favoring epcoritamab, with a hazard ratio of 0.74 and a 95% confidence interval of 0.60-0.92. Overall survival did not significantly differ, with a hazard ratio of 0.96 and a 95% confidence interval of 0.77-1.20.<\/p>\n The July 23 clarification stated that overall survival was the sole primary endpoint for the U.S. regulatory analysis and that this endpoint was not met. Outside the U.S., progression-free and overall survival were dual primary endpoints; the protocol also identifies overall survival as primary in China.<\/p>\n Epcoritamab received U.S. accelerated approval in May 2023 for adults with relapsed or refractory DLBCL and high-grade B-cell lymphoma after at least two prior lines, based on a 61% overall response rate, a 38% complete response rate, and a median response duration of 15.6 months.<\/p>\n A failed prespecified confirmatory endpoint is a major regulatory event when continued approval depends on verification of clinical benefit. The relevant U.S. endpoint is overall survival, not the globally positive progression-free-survival analysis. Treating the PFS result as if it satisfied the U.S. primary objective would misstate the evidentiary package.<\/p>\n Withdrawal is not automatic. FDA can examine the totality of evidence, including endpoint maturity, subsequent therapy, crossover, proportional-hazards behavior, subgroup consistency, safety, and other ongoing studies. The present evidence supports heightened regulatory risk, not a prediction of a predetermined agency action.<\/p>\n The PFS hazard ratio indicates a statistically significant but moderate reduction in progression or death versus older chemoimmunotherapy options. The OS hazard ratio near one suggests that this disease-control advantage did not translate into longer survival at the disclosed analysis.<\/p>\n Interpretation is constrained by the absence of medians, event counts, response durability, treatment exposure, adverse-event detail, subsequent therapy, and subgroup results. In aggressive lymphoma, access to CAR-T, other bispecific antibodies, transplantation, and salvage regimens after progression can materially influence overall survival.<\/p>\n Epcoritamab is a CD20\u00d7CD3 DuoBody bispecific antibody that brings cytotoxic T cells into contact with malignant B cells. Its subcutaneous dosing and off-the-shelf availability provide practical advantages over autologous CAR-T manufacturing, but continuous T-cell engagement creates risks including cytokine-release syndrome, infection, cytopenias, and immune suppression.<\/p>\n The result intensifies competition with glofitamab, other CD20 bispecifics, CAR-T products, and emerging combinations. Randomized evidence in transplant-ineligible patients remains useful, but failure on survival reduces the ability to claim decisive monotherapy differentiation and may shift development emphasis toward earlier-line combinations.<\/p>\n Genmab and AbbVie have additional epcoritamab studies across follicular lymphoma, DLBCL, and combination settings. Positive combination trials could strengthen the franchise but should not be assumed to cure the evidentiary weakness in this specific monotherapy confirmatory study.<\/p>\n The clarification is also a disclosure-governance signal: endpoint geography materially changes interpretation. Future monitoring should read protocol endpoint hierarchies and regional analysis plans rather than relying only on global topline language.<\/p>\n Diffuse large B-cell lymphoma is an aggressive mature B-cell malignancy. Patients who relapse after multiple therapies can receive CAR-T therapy, stem-cell transplantation when eligible, antibody-drug conjugates, CD20\u00d7CD3 bispecific antibodies, or chemotherapy-based salvage; choice is shaped by disease tempo, fitness, access, and prior treatment.<\/p>\n Epcoritamab-bysp, marketed as Epkinly, is a subcutaneous CD20\u00d7CD3 bispecific antibody developed by Genmab using its DuoBody platform and commercialized with AbbVie. It redirects endogenous T cells against CD20-expressing malignant B cells.<\/p>\n This is a high-priority hematology signal. It changes the interpretation of the Phase 3 result and places the accelerated DLBCL indication under meaningful regulatory uncertainty.<\/p>\n The correct posture is precise and non-binary: the U.S. confirmatory objective failed, but label action is not yet known. Full survival, safety, subsequent-treatment, and subgroup data will determine whether any evidentiary pathway remains.<\/p>\n Signal strength:<\/strong> 5\/5 \u2014 High. Importance:<\/strong> Very High \u2014 a failed sole U.S. primary endpoint directly affects the confirmatory evidence supporting an accelerated approval in a core hematologic malignancy. Confidence:<\/strong> High for the endpoint hierarchy, disclosed hazard ratios, accelerated-approval status, and sponsor clarification; medium for ultimate regulatory consequences because full data and FDA conclusions are not public.<\/p>\n","protected":false},"excerpt":{"rendered":" Genmab and AbbVie clarified on July 23 that overall survival \u2014 the sole U.S. primary endpoint in Phase 3 EPCORE DLBCL-1 \u2014 was not met. The randomized trial had previously shown a progression-free-survival hazard…<\/p>\n","protected":false},"author":1,"featured_media":2168,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[53,182,54],"class_list":["post-2147","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-abbvie","tag-diffuse-large-b-cell-lymphoma","tag-genmab"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2147"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2147\/revisions"}],"predecessor-version":[{"id":2179,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2147\/revisions\/2179"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2168"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Regulatory Interpretation<\/h4>\n
Clinical Interpretation<\/h4>\n
Mechanism and Competitive Context<\/h4>\n
Portfolio and Strategy<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n